Organogenesis Holdings Inc.
ORGO • NASDAQ
Organogenesis Holdings Inc. is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Gary S. Gillheeney, with a market cap of $310.0M.
Market Cap$310.0M
Employees862.0
CEOGary S. Gillheeney
CountryUnited States of America
Healthcare
Drug Manufacturers - Specialty & Generic
Next EarningsMay 7, 2026 · In 1 weekAfter Market Close · Q1 2026
Financials
Organogenesis Holdings Inc. FAQ
Common questions about Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is scheduled to report earnings for Q1 2026 on May 7, 2026 after market close. Analysts estimate revenue of $43.3M.
Organogenesis Holdings Inc. has approximately 862 employees.